Perampanel, a selective, non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, is a once-daily oral anti-seizure medication (ASM) for focal-onset seizures (FOS, previously referred to as partial-onset seizures) and generalized tonic-clonic (GTC) seizures (previously primary generalized tonic-clonic seizures) [1, 2]. In the US, perampanel is approved as an adjunctive treatment and monotherapy for FOS in patients aged ≥4 years, and as an adjunctive treatment for GTC seizures in patients aged ≥12 years [1].
27
FEB
FEB
0